Research

Mixed

Metabolic/bariatric surgery (MBS) is the most cost-effective intervention for class II and III obesity, often demonstrating dominance (cost-saving) over non-surgical management.

For individuals with Class II or III obesity, metabolic/bariatric surgery is the most economically and clinically effective long-term solution, often paying for itself through reduced healthcare costs from comorbidity remission. It should be prioritized over pharmacotherapy for this group.

GoodSupportsHIGH confidence
MBS offers the most durable weight loss, generally 25–30%, along with improvements in survival and quality of life. Economic evaluations consistently report MBS as highly cost-effective—and in some cases cost-saving—especially for class II and III obesity.
Yeon‐Ju Huh · Journal of Metabolic and Bariatric Surgery · 2025

Why this rating

Based on multiple economic modeling studies (lifetime, 20-year) across different countries (US, UK, Korea).

Source

Cost-Effectiveness of Obesity Treatments: Glucagon-Like Peptide-1 Receptor Agonists, Endoscopic Sleeve Gastroplasty, and Metabolic/Bariatric Surgery

Yeon‐Ju Huh · Journal of Metabolic and Bariatric Surgery · 2025

DOI 10.17476/jmbs.2025.14.2.97

narrative_reviewCited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →